These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21458579)

  • 21. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
    Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A
    Int J Biol Macromol; 2019 Jun; 131():396-411. PubMed ID: 30853582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aggresome formation and neurodegenerative diseases: therapeutic implications.
    Olzmann JA; Li L; Chin LS
    Curr Med Chem; 2008; 15(1):47-60. PubMed ID: 18220762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. J-domain proteins interaction with neurodegenerative disease-related proteins.
    Ayala Mariscal SM; Kirstein J
    Exp Cell Res; 2021 Feb; 399(2):112491. PubMed ID: 33460589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of neurodegeneration by molecular chaperones.
    Muchowski PJ; Wacker JL
    Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prion-Like Proteins in Phase Separation and Their Link to Disease.
    Sprunger ML; Jackrel ME
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of amyloidogenic protein oligomerization in neurodegenerative disease.
    Lotz GP; Legleiter J
    J Mol Med (Berl); 2013 Jun; 91(6):653-64. PubMed ID: 23529761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biophysical approaches for the study of interactions between molecular chaperones and protein aggregates.
    Wright MA; Aprile FA; Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Chem Commun (Camb); 2015 Oct; 51(77):14425-34. PubMed ID: 26328629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms and Functions of Spatial Protein Quality Control.
    Sontag EM; Samant RS; Frydman J
    Annu Rev Biochem; 2017 Jun; 86():97-122. PubMed ID: 28489421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chaperone AMPylation modulates aggregation and toxicity of neurodegenerative disease-associated polypeptides.
    Truttmann MC; Pincus D; Ploegh HL
    Proc Natl Acad Sci U S A; 2018 May; 115(22):E5008-E5017. PubMed ID: 29760078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality control of the proteins associated with neurodegenerative diseases.
    Gao X; Hu H
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):612-8. PubMed ID: 18604452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases?
    Lee HG; Petersen RB; Zhu X; Honda K; Aliev G; Smith MA; Perry G
    Brain Pathol; 2003 Oct; 13(4):630-8. PubMed ID: 14655766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases.
    Cremades N; Dobson CM
    Neurobiol Dis; 2018 Jan; 109(Pt B):178-190. PubMed ID: 28709995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging roles of J proteins in neurodegenerative disorders.
    Gibbs SJ; Braun JE
    Neurobiol Dis; 2008 Nov; 32(2):196-9. PubMed ID: 18760363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disentangling a Bad Reputation: Changing Perceptions of Amyloids.
    Wang M; Audas TE; Lee S
    Trends Cell Biol; 2017 Jul; 27(7):465-467. PubMed ID: 28359692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
    Bohush A; Bieganowski P; Filipek A
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytosolic protein quality control system--the role of molecular chaperones in the biology of neurodegenerative diseases].
    Guenther I; Kedzierska-Mieszkowska S
    Postepy Biochem; 2011; 57(3):274-82. PubMed ID: 22235653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.